Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) Stock Overview
Explore Vertex Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
119.2B
P/E Ratio
30.45
EPS (TTM)
$15.12
ROE
0.23%
VRTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Vertex Pharmaceuticals Incorporated (VRTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 51.07, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $549.09.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 30.45 and a market capitalization of 119.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.